Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

ABSTRACT: Single cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

PROVIDER: PRJNA687070 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Single cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

Project description:Single cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

| PRJNA687071 | ENA

Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib.

Project description: Not available

| S-EPMC7948271 | biostudies-literature

A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy

Project description:A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy

| PRJNA669680 | ENA

scRNAseq reveals mechanisms of Merkel cell carcinoma acquired immunotherapy resistance [1]

Project description:scRNAseq reveals mechanisms of Merkel cell carcinoma acquired immunotherapy resistance [1]

| PRJNA483959 | ENA

scRNAseq reveals mechanisms of Merkel cell carcinoma acquired immunotherapy resistance [2]

Project description:scRNAseq reveals mechanisms of Merkel cell carcinoma acquired immunotherapy resistance [2]

| PRJNA484204 | ENA

Studying human embryonic stem cell reveals molecular mechanisms of cold resistance

Project description:Studying human embryonic stem cell reveals molecular mechanisms of cold resistance

| PRJNA743312 | ENA

Deep sequencing of pyrethroid-resistant bed bugs reveals multiple mechanisms of resistance within a single population

Project description:A frightening resurgence of bed bug infestations has occurred over the last 10 years in the US. Current chemical methods have been inadequate for controlling bed bugs due to widespread insecticide resistance. Little is known about the mechanisms of resistance present in US bed bug populations, making it extremely difficult to develop intelligent strategies to control this pest. We have identified bed bugs collected in Richmond, VA which exhibit both kdr-type (L925I) and metabolic resistance to pyrethroid insecticides. LD50 bioassays determined resistance ratios of ~6000-fold to the insecticide deltamethrin, with contact bioassays confirming cross-resistance to several other labeled formulations. To identify metabolic genes potentially involved in the detoxification of pyrethroids, we performed deep-sequencing of the adult bed bug transcriptome, obtaining more than 2.5 million reads on the 454 titanium platform. Following assembly, analysis of newly identified gene transcripts in both Harlan (susceptible) and Richmond (resistant) bed bugs revealed several candidate cytochrome P450 and carboxyesterase genes which were significantly over-expressed in the resistant strain, consistent with the idea of increased metabolic resistance. These data will accelerate efforts to understand the biochemical basis for insecticide resistance in bed bugs, and provide molecular markers to assist in the surveillance of metabolic resistance. Deep sequencing was performed from total RNA isolated from adult male bed bugs using the Titanium 454 platform

2011-10-19 | E-GEOD-31025 | biostudies-arrayexpress

A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy

Project description:CD3-bispecific antibodies represent an important therapeutic strategy in oncology. These molecules work by redirecting cytotoxic T cells to antigen-bearing tumor cells. Although CD3-bispecific antibodies have been developed for several clinical indications, cases of cancer-derived resistance are an emerging limitation to the more generalized application of these molecules. Here, we devised whole-genome CRISPR screens to identify cancer resistance mechanisms to CD3-bispecific antibodies across multiple targets and cancer types. By validating the screen hits, we found that deficiency in IFNγ signaling has a prominent role in cancer resistance. Interestingly, IFNγ functions by stimulating the expression of T cell killing-related molecules in a cell type-specific manner. Additionally, by assessing resistance to the clinical CD3-bispecific antibody flotetuzumab, we identified core fucosylation as a novel and critical pathway to regulate flotetuzumab binding to the CD123 antigen. Disruption of this pathway resulted in significant resistance to flotetuzumab treatment. Moreover, proper fucosylation of CD123 is required for its normal biological functions. In order to treat the resistance associated with fucosylation loss, flotetuzumab in combination with an alternative targeting CD3-bispecific antibody demonstrated superior efficacy. Together, our study reveals multiple mechanisms that can be targeted to enhance the clinical potential of current and future T cell engaging CD3-bispecific antibody therapies.

2020-11-12 | GSE159547 | GEO

Transposon mutagenesis reveals fludarabine-resistance mechanisms in chronic lymphocytic leukemia

Project description:Purpose:To identify resistance mechanisms for the chemotherapeutic drug fludarabine in chronic lymphocytic leukemia (CLL), as innate and acquired resistance to fludarabine-based chemotherapy represents a major challenge for long-term disease control. Methods: We employed piggyBac transposon-mediated mutagenesis, combined with next-generation sequencing, to identify genes that confer resistance to fludarabine in a human CLL cell line. Results: RNA-seq profiling of fludarabine-resistant cells suggested deregulated MAPK signaling as involved in mediating drug resistance in CLL. To address if the fludarabine-resistant HG3 cells were transcriptionally different at a global level compared to their parental cells, we performed RNA-sequencing of three pairs of HG3 pools

2016-03-31 | E-GEOD-75844 | biostudies-arrayexpress

Immunosubtyping of breast cancer reveals distinct myeloid cell biology and immunotherapy resistance mechanisms

Project description:Immunosubtyping of breast cancer reveals distinct myeloid cell biology and immunotherapy resistance mechanisms

| PRJNA413800 | ENA